Cochrane · systematic review · CD003233

Interventions for focal segmental glomerulosclerosis in adults

Hodson, EM, Sinha, A, Cooper, TE · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library

Kidney and TransplantAMSTAR 2: not assessed

SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.

Questions

current version

GRADE rated

No studies

Included studies

No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 14.3%Low 6 · 85.7%Moderate 0 · 0%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Cyclosporin versus different comparators for focal segmental glomerulosclerosis in adults

Population: adults with FSGS

7 questions

Outcome	Effect	Evidence	Status / GRADE
Complete remission of proteinuria Cyclosporin vs different comparators	RR 2.31 [1.13, 4.73]	4 studies · 231 participants	Low Downgraded: imprecision
Partial remission of proteinuria Cyclosporin vs different comparators	RR 1.36 [0.78, 2.39]	4 studies · 231 participants	Low Downgraded: imprecision
Complete or partial remission Cyclosporin vs different comparators	RR 1.64 [1.1, 2.44]	4 studies · 231 participants	Low Downgraded: imprecision
Chronic kidney disease Cyclosporin vs different comparators	RR 0.83 [0.35, 1.96]	4 studies · 231 participants	Low Downgraded: imprecision
Kidney failure Cyclosporin vs different comparators	RR 0.55 [0.15, 2]	4 studies · 231 participants	Low Downgraded: imprecision
Adverse effects: hypertension Cyclosporin vs different comparators	no estimate extracted	2 studies · 187 participants	Very low Downgraded: imprecision
Adverse effects: infection Cyclosporin vs different comparators	no estimate extracted	2 studies · 157 participants	Low Downgraded: imprecision